Trials / Completed
CompletedNCT03902535
Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers
Geriatric Assessment and Quality of Life in Older Adults Undergoing Definitive Treatment for Head and Neck or Lung Cancer and Their Informal Caregivers
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 28 (actual)
- Sponsor
- City of Hope Medical Center · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Accepted
Summary
This trial studies comprehensive geriatric and quality of life assessments in older patients with head and neck or lung cancer that has or has not spread to other parts of the body who are undergoing standard surgery or chemoradiation, and their caregivers. Comprehensive geriatric assessment may improve the quality of life of patients with head and neck or lung cancer and their caregivers.
Detailed description
PRIMARY OBJECTIVES: I. To describe the patterns and distribution of comprehensive geriatric assessment (CGA) scores and physical activity levels and quality of life measures in older (\>= 65) patients with non-metastatic or metastatic head and neck or lung cancer undergoing upfront surgery followed (may be followed by adjuvant therapy) or upfront definitive radiation (with or without chemotherapy at the same time) to cure the disease. II. To describe the incidence and type of grade 2-5 toxicities in this patient population. III. To describe the family caregiver (FCG)-reported caregiving burden level and quality of life (QOL) scores. SECONDARY OBJECTIVES: I. To identify areas of vulnerability in this patient population using the geriatric assessment. II. To identify potential referrals based on geriatric assessment results. III. To describe other healthcare resource use and potential treatment modifications (unplanned hospitalization, emergency room (ER) visits, readmission rates, breaks in radiation and/or chemoradiation (CRT), dose modifications). IV. To explore changes in geriatric assessment and patient-reported symptoms, QOL, weight, and functional status from pre-treatment to 3-months, 6 months post-treatment. V. To explore changes in family caregiver (FCG)-reported caregiving burden and QOL from pre-treatment to 3-months, 6 months post-treatment. VI. To explore the relationship between geriatric assessment results and patient-reported symptoms and QOL. OUTLINE: Participants are assigned to 1 of 2 groups. GROUP I: Patients complete comprehensive geriatric and quality of life assessments within 1-4 weeks of treatment (either upfront surgery which may be followed by radiation with or without chemotherapy or upfront radiation which may include CRT) initiation (baseline), and at 1, 3, and 6 months following CRT completion. GROUP II: Family caregivers complete quality of life assessment at baseline, and at 1, 3, and 6 months following patient radiation or CRT completion.
Conditions
- Caregiver
- Head and Neck Carcinoma
- Lung Carcinoma
- Metastatic Head and Neck Carcinoma
- Metastatic Lung Carcinoma
- Stage 0 Lung Cancer AJCC v8
- Stage I Lung Cancer AJCC v8
- Stage IA1 Lung Cancer AJCC v8
- Stage IA2 Lung Cancer AJCC v8
- Stage IA3 Lung Cancer AJCC v8
- Stage IB Lung Cancer AJCC v8
- Stage II Lung Cancer AJCC v8
- Stage IIA Lung Cancer AJCC v8
- Stage IIB Lung Cancer AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Comprehensive Geriatric Assessment | Complete comprehensive geriatric assessment |
| OTHER | Quality-of-Life Assessment | Complete quality of life assessment |
| OTHER | Questionnaire Administration | Complete questionnaires |
Timeline
- Start date
- 2019-03-08
- Primary completion
- 2022-06-17
- Completion
- 2022-06-17
- First posted
- 2019-04-04
- Last updated
- 2023-02-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03902535. Inclusion in this directory is not an endorsement.